3.3.8. Uchida–Kraepelin Results

Table 10 shows the correct answer rates in the Uchida–Kraepelin test. The correct answer rate in the first half increased significantly in weeks 8 and 12 of intake of *Euglena* 1000 mg (*p* = 0.009, and *p* = 0.020, respectively, Dunnett's test).

**Table 10.** Correct answer rates (%) for the Uchida–Kraepelin test. After accounting for normality, a two-way repeated measure ANOVA was performed. The results showed a main effect of group (*p* = 0.098) in "First half;" therefore, we followed up with post-hoc comparisons using Dunnett's test. Dunnett's test was used for intergroup comparisons of mean values in the placebo group and *Euglena* intake groups at 0, 4, 8, and 12 weeks.


\*\* *p* < 0.01, \* *p* < 0.05, † *p* < 0.1 vs. the placebo intake group.

The correct answer rate in the first half tended to increase in week 8 with the continuous intake of *Euglena* 500 mg (*p* = 0.083, Dunnett's test), in week 12 with the continuous intake of *Euglena* 3000 mg (*p* = 0.067, Dunnett's test).
